Buy, $774.27 target, 20.7% upside: AI ad pricing outpaces 2027 depreciation
We initiate on Meta Platforms at Buy (Low conviction) with a 12-month target of $774.27 (+20.7% price return; +21.1% total return). Meta monetises 3.64bn daily active people across Facebook, Instagram, WhatsApp and Threads via AI-ranked ads. At $641.37 (21.8x published forward P/E; 20.3x on our FY27E EPS), the stock double-discounts AI capex.
- AI ranking sustains 21.0% FY27E ad growth, 8.5pp above the 12.5% price-implied rate. GEM and Andromeda lifted 3Q26 ad pricing +14.0% on +10.0% impressions, backing 22.94x peer P/E (+$75.47/sh vs price).
- Assumed FY27E capex of $234.9bn (75.0% of sales) places EPS 7.0% below Street, not P/E. D&A ($47.6bn), cloud/serving costs (36.5%) and +2.8% dilution put FY27E EPS at $31.58 vs $33.97 Street (−$54.92/sh).
- 4Q26E–FY28E cash needs (~$195bn: −$133.2bn FCF, $47.0bn RSU taxes, $15.1bn divs) still require ~$35bn of FY28E notes. Cash draw ($42.4bn), closed 4Q26 raises ($29.4bn), fwd/ATM equity ($88.7bn; +3.6% FY27E shs) and $34.9bn FY28E notes hold a $40bn floor.
What the market is missing. Consensus $312.6bn FY27E sales (+0.2% gap) and $33.97 EPS imply ~34% EBIT margin, under-modelling D&A, cloud costs and dilution (ours 32.5%, $31.58 EPS), while equity prices 20.55x.
Catalysts. Class C 1-for-1 dividend (~19 Jan 2027); 4Q26 & FY27 capex guide (late Jan 2027 est., +$4.80 / −$11.90/sh); AG trials (1H27); Muse & Meta One (+$8.20/sh).
Valuation and target. Peer-median 22.94x on $31.58 FY27E EPS less $7.51/sh legal accruals = $716.84 base; Bear ($448.05, 25%) / Base ($716.84, 55%) / Bull ($962.94, 20%) = $698.86, rolling 12M to $774.27 (DCF $502.26 on negative FCF; Low conviction: +1pt rate or 1.57 beta = Hold).
Risks. Policy slowing FY27E ad pricing to +6.5% (−$47.20/sh), FoA cash costs at 38.5% (−$45.00/sh), or FY27E capex above $250bn (−$11.90/sh).
| Dec YE, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Revenue | 164,501 | 200,966 | 257,086 | 313,139 | 368,416 |
| Growth y/y | 21.9% | 22.2% | 27.9% | 21.8% | 17.7% |
| EBITDA | 84,878 | 101,892 | 108,834 | 149,431 | 184,169 |
| Margin | 51.6% | 50.7% | 42.3% | 47.7% | 50.0% |
| Net income | 62,360 | 60,458 | 74,440 | 84,295 | 91,517 |
| Adj. EPS ($)* | 23.86 | 23.49 | 33.42 | 31.58 | 33.69 |
| Growth y/y* | 60.4% | −1.5% | 42.3% | −5.5% | 6.7% |
| Free cash flow | 52,103 | 43,585 | −1,421 | −80,555 | −40,151 |
| At $641.37, 9 Nov | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| P/E (adj.) | 26.9x | 27.3x | 19.2x | 20.3x | 19.0x |
| EV/EBITDA† | 19.3x | 16.0x | 15.0x | 10.9x | 8.9x |
| P/B | 9.2x | 7.6x | 5.3x | 3.7x | 3.0x |
| FCF yield | 3.1% | 2.6% | −0.1% | −4.7% | −2.3% |
| Dividend yield | 0.3% | 0.3% | 0.3% | 0.3% | 0.4% |
| ROE (adj.) | 37.1% | 30.2% | 32.4% | 21.9% | 17.5% |
| Net debt / EBITDA | −0.6x | −0.2x | 0.0x | 0.4x | 0.5x |
| P/E at $774.27 target | 32.5x | 33.0x | 23.2x | 24.5x | 23.0x |
Source: Company filings; Penmark Research model at 9 Nov 2026. *Adj. EPS ex $11.89bn FY26E AG charges (GAAP $28.89); FY26E includes a $5.0bn 1Q26 tax benefit (6.5% tax rate vs 16% FY27E). †Model EV $1,634.0bn (2,646.2m dil. shs × $641.37 − $63.2bn net cash/bridge; 3Q26 basic EV $1,640.7bn).
Base value is $716.84, or $794.19 rolled 12M; weighted $774.27 target offers 2.94x upside-to-downside
Source: Nasdaq closes to 9 Nov 2026; Penmark Research model (rolled 12M at 10.79% net of 0.34% yield).
FY27E ad +24.9% (+11.0% imp., +12.5% price), FoA cash cost 35.0%, capex 68% ($220.9bn), 27.20x P/E ($962.94 at 9 Nov).
FY27E ad +21.0% (+9.0% imp., +11.0% price), FoA cash cost 36.5%, capex 75%, 22.94x peer P/E ($716.84 at 9 Nov).
FY27E ad +14.0% (+7.0% imp., +6.5% price), FoA cost 38.5%, capex 88% ($258.7bn), $15bn legal, 18.10x P/E ($448.05 at 9 Nov).
| Income stmt, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Revenue | 164,501 | 200,966 | 257,086 | 313,139 | 368,416 |
| FoA & RL opex | 79,623 | 99,074 | 148,252 | 163,708 | 184,248 |
| EBITDA | 84,878 | 101,892 | 108,834 | 149,431 | 184,169 |
| Deprec. & amort. | 15,498 | 18,616 | 27,783 | 47,638 | 70,519 |
| EBIT (GAAP) | 69,380 | 83,276 | 81,051 | 101,793 | 113,650 |
| EBIT margin | 42.2% | 41.4% | 31.5% | 32.5% | 30.8% |
| Net fin. items | 1,283 | 2,656 | −1,400 | −1,442 | −3,388 |
| Income tax | 8,303 | 25,474 | 5,211 | 16,056 | 18,744 |
| Net income* | 62,360 | 60,458 | 74,440 | 84,295 | 91,517 |
| Cash flow, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| EBITDA | 84,878 | 101,892 | 108,834 | 149,431 | 184,169 |
| SBC & working cap. | 13,470 | 36,726 | 36,355 | 22,367 | 40,967 |
| Tax & net int. paid | −7,020 | −22,818 | −6,610 | −17,498 | −22,133 |
| Operating CF | 91,328 | 115,800 | 138,579 | 154,300 | 203,003 |
| Capex incl. leases | −39,225 | −72,215 | −140,000 | −234,854 | −243,155 |
| Free cash flow | 52,103 | 43,585 | −1,421 | −80,555 | −40,151 |
| Divs & buybacks | −35,197 | −31,572 | −5,440 | −5,766 | −6,112 |
| Eq., notes & RSU† | −4,494 | −8,236 | 18,726 | 37,663 | 41,464 |
| Chg. in cash & sec. | 12,412 | 3,777 | 11,865 | −48,658 | −4,799 |
| Balance sheet, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Cash & securities | 77,815 | 81,592 | 93,457 | 44,799 | 40,000 |
| Receivables | 16,994 | 19,769 | 26,432 | 27,453 | 32,300 |
| Net PP&E | 121,346 | 176,400 | 299,129 | 486,345 | 658,981 |
| Goodwill & other | 59,899 | 88,260 | 120,449 | 120,449 | 120,449 |
| Total assets | 276,054 | 366,021 | 539,467 | 679,047 | 851,729 |
| Gross debt | 28,826 | 58,744 | 98,669 | 98,669 | 133,541 |
| Net cash / (debt) | 48,989 | 22,848 | −5,212 | −53,870 | −93,541 |
| Total equity | 182,637 | 217,243 | 310,215 | 459,287 | 588,125 |
| Per share & KPIs | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Diluted shares (m) | 2,614 | 2,574 | 2,576 | 2,670 | 2,716 |
| EPS, adjusted ($)* | 23.86 | 23.49 | 33.42 | 31.58 | 33.69 |
| EPS, GAAP ($) | 23.86 | 23.49 | 28.89 | 31.58 | 33.69 |
| Common div. / sh ($) | 1.94 | 2.07 | 2.11 | 2.16 | 2.25 |
| FCF / share ($) | 19.93 | 16.93 | −0.55 | −30.17 | −14.78 |
| Book value / sh ($) | 69.87 | 84.40 | 120.42 | 172.04 | 216.51 |
| Ad impressions y/y | 11.0% | 12.0% | — | 9.0% | 8.0% |
| Avg price / ad y/y | 10.0% | 9.0% | — | 11.0% | 8.0% |
Source: Company filings; Penmark Research model. *FY26E adj. EPS ($33.42) sums 9M26A ($24.98) + 4Q26E ($8.45) ex $11,890m legal charges (GAAP EPS $28.89); FY26E includes a $5.0bn 1Q26 tax benefit (6.5% tax rate vs 16% FY27E). †Equity/preferred & notes issued less RSU settlement taxes, preferred dividends and other cash/securities items.
EBITDA margin rebounds to 50.0% by FY28E; our FY27E EPS is 7.0% below Street on D&A
| Growth & margins | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Growth y/y (%) | |||||
| Sales | 21.9% | 22.2% | 27.9% | 21.8% | 17.7% |
| EBITDA | 46.5% | 20.0% | 6.8% | 37.3% | 23.2% |
| EBIT (GAAP) | 48.4% | 20.0% | −2.7% | 25.6% | 11.6% |
| Adj. EPS* | 60.4% | −1.5% | 42.3% | −5.5% | 6.7% |
| Common div. / dil. sh | n/a | 6.7% | 1.9% | 2.4% | 4.2% |
| Margins & coverage | |||||
| FoA cash cost / FoA rev. | 26.5% | 28.8% | 34.3% | 36.5% | 36.0% |
| EBITDA margin | 51.6% | 50.7% | 42.3% | 47.7% | 50.0% |
| EBIT margin | 42.2% | 41.4% | 31.5% | 32.5% | 30.8% |
| FCF margin | 31.7% | 21.7% | −0.6% | −25.7% | −10.9% |
| EBITDA / gross int. | 93.2x | 51.6x | 33.2x | 27.3x | 28.9x |
| Capex / sales | 23.8% | 35.9% | 54.5% | 75.0% | 66.0% |
| Ratios & valuation | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Returns & leverage | |||||
| ROE (adj.) | 37.1% | 30.2% | 32.4% | 21.9% | 17.5% |
| ROA | 24.7% | 18.8% | 16.4% | 13.8% | 12.0% |
| ROCE | 36.2% | 34.2% | 23.7% | 21.1% | 17.8% |
| Net debt / equity | −26.8% | −10.5% | 1.7% | 11.7% | 15.9% |
| Net debt / EBITDA | −0.58x | −0.22x | 0.05x | 0.36x | 0.51x |
| Valuation at $641.37 (9 Nov 2026) | |||||
| P/E (adj.) | 26.9x | 27.3x | 19.2x | 20.3x | 19.0x |
| P/E (GAAP) | 26.9x | 27.3x | 22.2x | 20.3x | 19.0x |
| EV/EBITDA† | 19.3x | 16.0x | 15.0x | 10.9x | 8.9x |
| P/B | 9.2x | 7.6x | 5.3x | 3.7x | 3.0x |
| FCF yield | 3.1% | 2.6% | −0.1% | −4.7% | −2.3% |
| P/E at $774.27 target | 32.5x | 33.0x | 23.2x | 24.5x | 23.0x |
Source: Company filings; Penmark Research model at $641.37 (9 Nov 2026); FY27E yield 0.34%. *FY26E includes a $5.0bn 1Q26 tax benefit (6.5% tax rate vs 16% FY27E). †Model EV $1,634.0bn (2,646.2m dil. shs × $641.37 − $63.2bn net cash/bridge; 3Q26 basic EV $1,640.7bn).
| Penmark vs Street | 4Q26E | FY26E | FY27E |
|---|---|---|---|
| Revenue ($m) | |||
| Penmark estimate | 75,373 | 257,086 | 313,139 |
| Consensus | 75,155 | 256,876 | 312,630 |
| Prior-year period | 59,893 | 200,966 | 257,086 |
| Diff. vs consensus | +0.3% | +0.1% | +0.2% |
| Growth y/y (Penmark) | +25.8% | +27.9% | +21.8% |
| Diluted EPS ($, GAAP basis vs Street) | |||
| Penmark estimate | 8.45 | 28.89 | 31.58 |
| Consensus | — | 29.12 | 33.97 |
| Prior-year period | — | 23.49 | 28.89 |
| Diff. vs consensus | — | −0.8% | −7.0% |
| Growth y/y (Penmark) | — | +23.0% | +9.3% |
Source: Yahoo Finance consensus (10 Nov 2026; 44–59 analysts); Penmark Research model. 4Q26E is the modelled quarterly revenue/EPS stub (guide $73.0bn–$76.0bn).
Source: Filings (A); Penmark Adj. EPS ex AG charges (E); Street GAAP EPS ticks (10 Nov 2026). *FY26E includes a $5.0bn tax benefit booked in 1Q26; the FY26E tax rate is 6.5% vs 16% in FY27E.
At 21.8x published forward P/E, 5.0% below the 22.94x peer median and 20.3x on our FY27E EPS, META discounts peak capex
| At 9 Nov 2026 prices | META | Peer med. | Diff. |
|---|---|---|---|
| Valuation multiples | |||
| Forward P/E (published) | 21.8x | 22.94x | −5.0% |
| P/E on our FY27E EPS | 20.3x | 22.94x | −11.5% |
| P/E at $774.27 target | 24.5x | 22.94x | +6.9% |
| Trailing P/E | 21.9x | 24.3x | −9.9% |
| Operating & scale benchmarks | |||
| Latest qtr sales y/y | 26.1% | 21.8% | +4.3pp |
| Latest op. margin (adj.)* | 35.4% | 31.8% | +3.6pp |
| Latest op. margin (GAAP) | 20.1% | 31.8% | −11.7pp |
| Market value ($bn) | 1,639.5 | 3,206.5 | −48.9% |
Source: Penmark Research model (6 Nov published forward EPS at 9 Nov close: GOOGL 18.10x, APP 20.83x, AMZN 25.05x, MSFT 27.20x; median 22.94x). *META 3Q26 ex $9.89bn AG charge (20.1% GAAP; 3-peer op. margin median).
- 19 Jan 27Class C 1-for-1 non-voting stock dividend effective; expands equity currency without diluting Class B control.
- Late JanEst. 4Q26 results ($75.4bn vs $75.2bn Street) and formal FY27 capex/opex guide (+$4.80 bull / −$11.90/sh bear).
- 1H 2027Youth & state AG benchmark trials; tests $19.9bn accrued legal reserve (−$4.90/sh for $15.3bn extra charges).
- 2H 2027Muse commerce & Meta One scaling toward $7.4bn FY27E FoA Other sales (+75% y/y; +$8.20/sh bull).
Source: Company 8-K/10-Q filings; Penmark Research model.
- Ad pricing slowdown. Regulatory limits cut FY27E ad price growth to +6.5%. Med; −$47.20/sh.
- FoA opex creep. AI compute pushes FoA cash cost ratio to 38.5%. Med; −$45.00/sh.
- Runaway FY27E capex. Spend exceeds $258.7bn (88% of sales) or 10Y rates +1pt. Med; −$11.90 to −$121.00/sh.
- Upside risk vs Low conviction. Ad growth hits +24.9% and capex holds 68% ($220.9bn), rerating to 27.2x. 20% prob.; +$246.10/sh.
Source: Penmark Research model scenario & sensitivity matrix.
Source: Company quarterly filings and Nasdaq quarter-end closes, 4Q21–3Q26; Penmark Research model (3Q26 $725.18 close; at $641.37 on 9 Nov, 21.8x published fwd P/E or 20.3x on our FY27E EPS).
Source: Penmark Research model (META and four valuation peers on 6 Nov published forward EPS priced at 9 Nov 2026 close; META is 20.3x on our FY27E EPS).
| Monitoring KPI | Thesis confirmed if | Broken (cut to Hold) if | Per-share model sensitivity |
|---|---|---|---|
| Ad price growth (D1) | ≥ +10% y/y through 1H27 | < +6.5% y/y for two quarters | ±$19.43/sh per ±2pp (−$47.20 Bear) |
| FY27E capex guide (D2/D3) | ≤ $235bn (≤ 75% of sales) | > $255bn without ad-yield lift | +$4.80/sh at $221bn / −$11.90 at $259bn |
| FoA cash cost ratio (D2) | ≤ 36.5% of FoA revenue | ≥ 38.5% on serving/cloud opex | ∓$44.86/sh per ±2pp (−$45.00 Bear) |
| WACC / Equity beta | WACC ≤ 10.80% (beta 1.25) | +1pt rate or 1.57 beta | $650.78 (+1.5%) or $598.85 (−6.6%) = Hold |
What would change our view: At $641.37, any target below $705.51 (+10.0%) moves META to Hold; we would upgrade conviction if 4Q26 guidance caps FY27E capex near $220bn while ad pricing holds ≥ +11%.
Six exhibits trace the call from TTM EBIT, a 0.91 correlation, and +14% ad pricing to our $716.84 base value
Meta’s share price tracks trailing operating profit over multi-year cycles, while quarterly sell-offs track capex surprises. Our model puts FY27E EPS 7.0% below Street ($31.58 vs $33.97) on D&A, cloud costs and dilution yet still derives $716.84 base value ($774.27 12M target) at peer-median 22.94x P/E.
Source: Company quarterly filings & Nasdaq quarter-end closes, 4Q21–3Q26 (descriptive r = 0.913, n = 20; 9 Nov model price $641.37).
Source: Meta Form 10-K and 10-Q MD&A, 4Q24–3Q26.
Source: Company filings (A); Penmark Research capex incl. leases (E, 75% FY27E assumption); Street FCF-implied $217.2bn (~30 Oct 2026).
Source: Yahoo Finance consensus (10 Nov 2026); Penmark Research model. *FY26E includes a $5.0bn 1Q26 tax benefit (6.5% tax rate vs 16% FY27E).
Source: Company quarterly filings and Nasdaq closes to 30 Sep 2026; Penmark Research model.
Source: Penmark Research model at 9 Nov 2026.
Four debates pit +$75.47/sh of P/E upside vs price against −$54.92/sh of D&A/cost drag vs Street
Equity pricing ($641.37) and sell-side consensus ($833.12 average target) commit opposite errors on Meta’s AI infrastructure cycle. The share price implies 20.55x our FY27E EPS (21.8x published forward P/E), whereas consensus EPS under-counts 2027 D&A, cloud costs and dilution by $2.39/sh.
| Debate | Market view | Penmark view | Primary evidence | What changes our view | Resolves |
|---|---|---|---|---|---|
| 1. AI ad pricing & multiple (Ch. 10) | Stock prices 20.55x FY27E EPS (12.5% implied ad growth) on negative FCF. | 22.94x peer-median P/E on +21.0% FY27E ad growth (+$75.47/sh vs price). | 3Q26 ad price +14.0%; GEM +9.6% app conversions; 10m GenAI ad tool users. | Two quarters of ad price growth below +7.0% y/y or ad growth <14%. | Jul 2027 |
| 2. FY27E D&A & cost step-up (Ch. 11) | Consensus $33.97 FY27E EPS implies ~34% EBIT margin on $312.6bn sales. | $31.58 FY27E EPS (32.5% EBIT margin) on D&A, cloud costs & dilution (−$54.92/sh). | FY26E capex $140bn & 3Q26 opex +68%; 39 Street EPS cuts in 30 days. | Server useful-life extension or FoA cash costs below 35.0% of revenue. | Q1 2027 |
| 3. Peak capex & funding plan (Ch. 12) | Bear estimates of $250bn+ after the 3Q26 print ($711.38/sh at market view). | Assumed $234.9bn FY27E capex (75% rev; +$5.47/sh vs bear); ~$195bn 4Q26–28E need incl. $35bn FY28E notes. | $454.5bn commitments ($121.4bn due 2027); $14.4bn pref & $15bn notes closed; $88.7bn fwd/ATM eq. | FY27 capex guide >$255bn (>80% rev) or 10Y Treasury yield +100bps. | Q1–Oct 27 |
| 4. Youth & state AG litigation (Sec. 17) | Headline fear of unquantified multi-state settlements after $9.89bn 3Q26 charge. | Deduct $19.88bn accrued legal liabilities ($7.51/sh) directly in base equity bridge. | 3Q26 10-Q accrues $11.58bn current + $8.30bn non-current; payments capped ~$18.6bn. | Adverse benchmark trial verdicts adding $15.3bn unaccrued charges (−$4.90/sh). | 1H 2027 |
Source: Meta Form 10-Q/8-K filings; Yahoo Finance consensus (10 Nov 2026); Penmark Research model.
Source: Penmark Research model (9 Nov 2026).
How the debates map to the thesis
Each confirmed stock driver in Section 9 links cleanly to our four debates. Debate 1 maps to Chapter 10 (22.94x peer P/E on +21.0% FY27E ad growth, +$75.47/sh vs $641.37). Debate 2 maps to Chapter 11 ($47.6bn D&A, cloud costs & dilution, −$54.92/sh vs Street EPS). Debate 3 maps to Chapter 12 ($234.9bn FY27E capex vs $250bn+ bear views, +$5.47/sh, & ~$195bn 4Q26–28E funding incl. $35bn notes to issue), and Debate 4 to Section 17 (+$4.84/sh vs $15.3bn new charges).
Why both Street and market pricing miss
Sell-side targets ($833.12 mean) apply peer multiples to unadjusted margins, while $641.37 applies 20.3x to our FY27E EPS. Once formal FY27 guidance aligns Street EPS toward ~$31.6, clearing capex fears supports rerating to 22.94x.
Source: Company Form 8-K and 10-Q filings; Penmark Research catalyst calendar.
3.64bn people pay nothing to use Meta every day, yet AI auctions turn each ad dollar into 41¢ of operating profit
Meta runs the world’s largest attention and commerce auction across Facebook, Instagram, WhatsApp and Threads. With $454.5bn of infrastructure commitments booked ($121.4bn due in 2027), we model $234.9bn of 2027 capex—three-quarters of sales—to rebuild around generative AI.
The scene
In 3Q26, nearly 10 million advertisers logged into Meta’s self-serve tools and let generative AI write copy, crop video or target buyers without an agency. Over the same weeks, more than 10 million US and Canadian users set up Muse, Meta’s personal AI assistant, where commerce emerged as the top use case at a >$200 average basket. Behind both sits a daily habit shared by 3.64bn people.
What it actually does
Meta sells predicted outcomes rather than thirty-second ad slots. Whenever a user scrolls Reels or Feed, neural ranking models—led by Meta’s Generative Ads Recommendation Model (GEM) and Andromeda retrieval engine—auction that slot across millions of merchants. The winner is the ad most likely to make that specific viewer buy, install or message.
How the money comes in
Advertising supplied $196.2bn (97.6%) of Meta’s $201.0bn FY25A revenue, paid per impression or conversion across uncapped self-serve budgets. FoA subscriptions and messaging added $2.6bn (1.3%) and Reality Labs devices added $2.2bn (1.1%). In FY25A, $1.00 of sales left 82.0¢ gross profit, 41.4¢ operating profit ($83.3bn) and 21.7¢ free cash flow ($43.6bn).
Where the story turns
After cutting staff in 2023 to lift operating margin above 41%, Mark Zuckerberg launched an unprecedented AI compute build. Capex including leases jumped from $39.2bn (FY24A) to $72.2bn (FY25A), $140.0bn (FY26E), and an assumed $234.9bn in FY27E—pushing FY27E FCF to −$80.6bn.
Why it works, and why it might not
Advertisers stay because AI conversion lifts (+9.6% app conversions on GEM; +9% spend for Business Assistant users) outpace ad price inflation. Capital intensity is the risk: if $234.9bn of GPUs fail to hold +11% FY27E ad pricing (D1) or capex tops $255bn (D3), D&A crushes returns.
Exhibit 26: One customer dollar, start to finish (built from FY25A and 3Q26 reported disclosures). Source: Meta filings; Penmark Research.
Family of Apps generated 98.9% of $201.0bn FY25A revenue and >100% of Meta’s $83.3bn operating profit
Source: Company filings; Penmark Research model. Figures are FY25A reported unless noted.
What Meta sells, and why 10m+ advertisers buy
Meta sells measurable customer acquisition across a unified 3.64bn-person daily social graph with zero single-customer concentration above 10%. Unlike open-web ad networks crippled by mobile identifier deprecation, Meta closes the loop inside first-party apps (Reels, Feed, Click-to-WhatsApp, Shops) using on-platform engagement and conversion APIs.
Pricing, operating leverage and cash conversion
Revenue equals Family of Apps ad impressions multiplied by auction-cleared price per ad, plus FoA subscriptions/messaging and Reality Labs hardware. Cash operating costs are largely fixed engineering payroll, while incremental cost is shifting from variable headcount (down 15% y/y in 3Q26 to 66,775) to capitalised GPU servers—turning FY25A’s $43.6bn FCF into −$80.6bn in FY27E despite $154.3bn of operating cash flow.
Of each $1 of FY25A sales, 82.0¢ was gross profit and 41.4¢ EBIT; North America drives 45.1% of ad revenue
R&D ($57.4bn, 28.6% of sales) exceeds COGS ($36.2bn) and SG&A ($24.1bn) combined. As first-party Muse models cut content-processing cost >80%, cash opex ratios fall while server D&A rises inside COGS and R&D.
Source: Meta FY2025 Form 10-K ($bn).
Source: Penmark Research model; Q3 2026 earnings call transcript. Shaded nodes highlight primary Section 14 forecast drivers.
US & Canada ($28.44bn) and Europe ($14.23bn) supply 67.7% of ad revenue.
Source: Meta Q3 2026 Form 10-Q geographic KPIs.
Quarterly FoA ARPP rose 24.4% (+$3.47) from 4Q24 to 3Q26 as DAP expanded +8.7%.
Source: Meta Form 10-Q and earnings releases, 4Q24–3Q26.
Global social advertising reaches $394.6bn in 2026E, up 21.3%, while Meta leads global digital ads at 26.8% share
Digital and social advertising are compounding nearly twice as fast as global all-media spend ($1.30tn–$1.34tn in 2026E). Generative AI creative tools and closed-loop conversion APIs are shifting performance budgets from open-web display and linear TV into first-party platforms.
Source: Meta Q3 2026 Form 10-Q and earnings call transcript; Penmark Research.
Source: eMarketer 2026 global digital ad projections (26.8% Meta, 26.4% Google, 9.0% Amazon; top-3 = 62.3% share). Scope differs from GAAP ad revenue ($250.7bn Penmark FY26E).
| Market benchmark | Size | Growth | Meta context |
|---|---|---|---|
| Global all-media (WARC 26E) | $1,340bn | +9.1% | WPP ex-US pol. $1.30tn |
| Global social ads (WARC 26E) | $394.6bn | +21.3% | Up from ~$325bn in 2025 |
| Global digital ads (eMkt 26E) | ~$908.5bn* | n/a | Meta est. 26.8% share |
| US internet ads (IAB 2025A) | $294.6bn | +13.9% | Secular shift from TV |
| US social media (IAB 2025A) | $117.7bn | +32.6% | 40.0% of US digital rev |
| Meta GAAP ad rev (FY26E) | $250.7bn | +27.8% | FY27E $303.3bn (+21.0%) |
Source: WARC, WPP Media, IAB/PwC, eMarketer (*implied from $243.46bn / 26.8%), Penmark model. Agency pools differ across China/retail media boundaries.
Bottom-up demand: units × price and cycle position
Social advertising is taking share because GenAI removes creative production bottlenecks for >10m small and mid-sized advertisers. In the US, IAB data show social revenue rose 32.6% to $117.7bn in 2025 (40.0% of internet ad spend), while WARC projects global social spend up 21.3% to $394.6bn in 2026. Meta’s +27.8% FY26E GAAP ad growth ($250.7bn vs $196.2bn FY25A) outpaces the broader market by >6pp.
Margin capture sits inside walled gardens, not open-web intermediaries. Because Meta owns consumer supply (Reels, Feed, Threads), creative automation (Advantage+), auction ranking (GEM/Andromeda) and messaging checkout, it bypasses third-party demand-side and supply-side take rates—earning an 82.0% FY25A gross margin.
Regulatory, AI search and substitution threats
Three structural forces could cap ad pricing power over 2027–2028: (1) European DMA / “consent-or-pay” rules restricting cross-app behavioural targeting across Europe’s $14.23bn quarterly ad pool; (2) US youth mental-health and state AG restrictions on teen engagement features; and (3) retail media networks (Amazon $82.1bn 2026E) and AI answer engines competing for bottom-funnel purchase intent.
Meta outgrows Alphabet, 26.1% vs 24.7%, and trades at 21.8x forward P/E vs 22.94x peer median
Meta’s moat rests on three self-reinforcing advantages: a 3.64bn daily social graph, closed-loop SMB auction liquidity, and hyperscale AI ranking. Among platforms able to fund $100bn+ annual AI infrastructure, Meta pairs faster top-line growth than GOOGL, AMZN and MSFT with unmonetised messaging and Reels surfaces.
Source: Penmark Research competitive assessment grounded in company filings and KPI disclosures across the four-company valuation peer set.
| Company (Ticker) | Primary overlap & business-model role | Market cap ($bn) | Latest rev y/y | Op. margin | Trail. P/E | Fwd P/E |
|---|---|---|---|---|---|---|
| Meta Platforms (META) | Subject: social, Reels, messaging & AI ads | $1,639.5 | 26.1% (3Q26) | 35.4%* | 21.9x | 21.8x |
| Alphabet (GOOGL) | YouTube video, Search intent & Gemini AI | $3,538.0 | 24.7% | 31.8% | 15.0x | 18.1x |
| Amazon (AMZN) | Closed-loop retail media ads & AWS cloud | $2,875.0 | 12.1% | 13.1% | 21.5x | 25.1x |
| Microsoft (MSFT) | Hyperscale AI capex, Copilot & LinkedIn ads | $4,003.0 | 18.8% | n/a | 28.4x | 27.2x |
| AppLovin (APP) | AI mobile performance ad-ranking engine | $135.8 | 55.5% | 77.8% | 27.1x | 20.8x |
| Peer median (4 peers) | Equal-ranked valuation benchmark | $3,206.5 | 21.8% | 31.8% | 24.3x | 22.94x |
| META vs peer median | Published fwd P/E (memo: 20.3x on our FY27E EPS) | −48.9% | +4.3pp | +3.6pp | −9.9% | −5.0% |
| Reddit (RDDT, ref. only) | Excluded: fell 31% post-29 Oct print; no 9 Nov fwd P/E | $19.5 | 53.0% | 29.4% | 19.6x | n/a |
| Pinterest (PINS, ref. only) | Excluded: no published forward P/E at 9 Nov price date | n/a | n/a | n/a | n/a | n/a |
Source: Penmark Research model (forward P/Es as published on 6 Nov and priced at 9 Nov 2026 close: GOOGL 18.10x, APP 20.83x, AMZN 25.05x, MSFT 27.20x; median 22.94x; statistics use four price-date peers only). *META 3Q26 op. margin ex $9.89bn AG charge (20.1% GAAP).
Why GOOGL, AMZN, MSFT and APP define the peer set
Only GOOGL, AMZN and MSFT match Meta’s $100bn+ annual AI data-centre commitment, while APP isolates pure-play AI ad-ranking economics. Smaller social platforms (Reddit at $19.5bn market cap, Pinterest at $19.06/sh) lack both hyperscale GPU budgets and published 9 November forward multiples. On the same 6 November published forward basis, Meta’s 21.8x P/E sits 5.0% below the 22.94x four-peer median despite faster revenue growth (+26.1% vs 21.8% median).
Durability of switching costs & unmonetised surfaces
Unlike GOOGL, AMZN and MSFT, Meta lacks an external enterprise cloud division (1/4 score), heightening free-cash-flow sensitivity during peak GPU capex. Offsetting that gap, nearly 10m advertisers use Meta’s generative creative tools, Partnership Ads exceed a $15bn run-rate (+97% y/y), and Threads plus WhatsApp business messaging expand auction supply organically without acquisition traffic costs.
Zuckerberg’s 60.8% vote enables a $234.9bn FY27E capex pivot while Class C preserves control
Meta is a founder-controlled company whose capital allocation has swung from $76.1bn of FY23A–25A buybacks to external infrastructure financing. Minority investors have zero voting check on capital intensity, making return on AI capex the central governance question.
| Governance dimension | Reported structure & proxy disclosure | Implication for minority shareholders |
|---|---|---|
| Founder voting control | Mark Zuckerberg holds 639,347 Class A (1 vote) and 341,823,978 Class B shares (10 votes) = 99.8% of Class B and 60.8% total voting power. | Unilateral approval of budgets, M&A, board slate and multi-year AI/Reality Labs spend without shareholder veto. |
| Class C non-voting dividend (~19 Jan 2027) | Board & majority vote approved non-voting Class C stock and a 1-for-1 Class C stock dividend for each Class A/B share. | Creates liquid non-voting equity for $60bn FY27E–28E ATM and RSU grants without diluting Zuckerberg’s 60.8% vote. |
| CEO pay & alignment | 2025 total CEO pay $25.13m ($1 base salary, $0 bonus/equity awards, $25.13m personal security & aircraft). | Direct ~$219bn equity stake aligns long-term wealth with share price, though time horizon exceeds 3–5 yr fund cycles. |
| Board & leadership bench | Combined Chair/CEO role with Lead Independent Director; CFO Susan Li leads disciplined hybrid capital structure. | Strong execution track record since 2023 efficiency reset (headcount 66,775 in 3Q26, −15% y/y), offset by key-person risk. |
| Capital shift (FY26E–28E) | Buybacks paused since 4Q25 ($0 in 9M26A and $0 modelled FY26E–30E); $14.4bn mandatory preferred + $15.0bn senior notes issued Oct–Nov 2026. | FY27E diluted shares are +3.6% vs FY26E (+2.8% vs consensus share count); by FY29E shares are +6.4% vs FY26E (2,740m). |
Source: Meta 2026 DEF 14A Proxy Statement (filed 16 Apr 2026); Form 8-K filings (21 Oct, 29 Oct, 5 Nov 2026); Penmark model.
Source: Company filings; Penmark Research model (FY23A–FY25A CFO $278.2bn: $139.5bn capex incl. leases, $76.1bn buybacks, $10.4bn dividends).
Source: Q1–Q3 2026 earnings releases; Yahoo Finance 4Q26 consensus ($75.16bn); Penmark Research model.
Guidance record: consistent top-line beats, rising capex
Quarterly revenue landed near the top of guidance in 1Q26 ($56.3bn vs $53.5bn–$56.5bn) and 2Q26 ($60.8bn vs $58.0bn–$61.0bn) and beat the top end in 3Q26 ($64.60bn vs $61.0bn–$64.0bn), while management lifted FY26 capex guidance to $135bn–$145bn. Our $75.37bn 4Q26E sits near the top of the $73bn–$76bn range (~1% FX headwind), whereas four of the last five results windows coincided with −5.8pp to −10.3pp 3-day excess sell-offs alongside higher spend guides.
Controlled-issuer governance trade-off
History cuts both ways on Zuckerberg’s unilateral bets. Reality Labs has accumulated >$70bn of operating losses (still −$18bn to −$19bn in FY26E, narrowing to −$15.0bn in FY27E), yet the 2022–2023 pivot to AI Reels ranking and staff discipline doubled TTM EBIT from $36.8bn to $79.4bn while trimming 3Q26 headcount 15% y/y to 66,775.
TTM EBIT drives 3-year returns of +$371.5/sh, while capex hikes coincided with four drops of −5.8pp to −10.3pp
Over three years (Nov 2023–Nov 2026), META doubled (+100.1% to $641.37) almost entirely on TTM EBIT expansion (+$371.54/sh), while multiple compression cost −$69.01/sh. Across four empirical tests, four company-specific drivers govern both earnings-day swings and medium-term re-rating.
| Confirmed driver | Tests passed | Observed market reaction | Penmark model value | Debate | Next number to watch |
|---|---|---|---|---|---|
| 1. AI ad pricing & yield | Event, 3Y bridge, Q&A (3/4) | 4Q25 +10.5pp excess rally on +24% rev & +6%→+12% price acceleration | ±2pp FY27E ad price = ±$19.4/sh (±2.7%); Bear +6.5% = −$47.2/sh | D1 | 4Q26 ad price y/y (est. late Jan 2027; Penmark ~+12%) |
| 2. AI capex & D&A path | Event, 3Y multiple, Q&A (3/4) | −5.8pp to −10.3pp 1-day excess drops when FY capex guide rose | +$5.47/sh vs $250bn+ bear capex view; −$11.90/sh above $250bn | D2, D3 | Initial FY27 capex guide (est. late Jan 2027; Penmark $234.9bn) |
| 3. Muse & FoA AI revenue | Event, Call Q&A #1 (2/4) | 55.4% of analyst Q&A turns; market assigns ~0x to AI assistants | FoA Other +75% to $7.40bn FY27E ($23.19bn by FY30E) | D3 | 2027 Muse commerce GMV & Meta One paid subs (>15m base) |
| 4. Cost of equity / beta | Factor R², Valuation (2/4) | 57.6% weekly variance from Market + XLC; rate spikes compress P/E | +1pt rate cuts base −$121.0/sh to $595.9 (wtd $582.1 / $650.8 tgt = Hold) | D1, D3 | Hybrid financing spreads & 10Y UST / sector beta regime |
Source: Nasdaq daily/weekly closes, company filings/transcripts and Penmark Research model.
| Release (Date) | Primary operational & capex surprise vs expectations | META 1D | S&P 500 | Excess |
|---|---|---|---|---|
| 3Q25 (29 Oct 25 AMC) | Ad rev beat, but management flagged materially higher FY26 AI capex growth | −11.33% | −0.99% | −10.34pp |
| 4Q25 (28 Jan 26 AMC) | Strong 1Q26 rev guide ($53.5bn–$56.5bn) outweighed initial FY26 capex frame | +10.40% | −0.13% | +10.53pp |
| 1Q26 (29 Apr 26 AMC) | Rev $56.3bn near top of guide (+12% price), but FY26 capex ceiling raised | −8.55% | +1.02% | −9.57pp |
| 2Q26 (29 Jul 26 AMC) | Rev $60.8bn beat (+14% imps, +12% price), offset by steeper 2H26/FY27 infra commentary | −7.95% | +1.66% | −9.61pp |
| 3Q26 (21 Oct 26 AMC) | Rev $64.6bn beat (+14% price), FY26 capex lifted to $135bn–$145bn + $9.89bn AG charge | −6.98% | −1.21% | −5.77pp |
Source: Nasdaq unadjusted daily closes around Form 8-K earnings timestamps; Penmark Research.
Source: Nasdaq and S&P Dow Jones Indices next-day excess return vs S&P 500. Notice diminishing sell-off (−10.3pp → −5.8pp) by 3Q26 as $140bn capex entered consensus.
Source: Penmark decomposition (9 Nov 23 $320.55 → 9 Nov 26 $641.37; TTM EBIT $36.77bn → $79.38bn; P/TTM EBIT/sh 23.03x → 20.79x). Excludes ~$6.1/sh cumulative dividends.
Idiosyncratic variance is 42.4% weekly; Muse/AI at 55.4% and capex at 32.3% top multi-coded Q&A
Source: Penmark OLS regression of weekly log returns (n = 262 weeks, Nov 2021–9 Nov 2026) on S&P 500 and XLC closes. Note: META (~22% XLC weight) inflates standalone XLC R².
Source: Penmark analyst topic coding across the last 8 quarterly earnings calls (n = 65 multi-part analyst Q&A turns; shares sum >100%).
Driver 1 · Ad pricing & yield beats set upside (Debate 1)
Claim: Sustained >10% ad price growth proves GPU capex earns an immediate cash return. Market prices 12.5% FY27E ad growth ($641.37), whereas our 21.0% build (+11% price, +9% imps) adds +$75.47/sh to our $716.84 base value (+11.8%). Watch: 4Q26 ad price y/y (est. late Jan 2027) — Penmark +12%; >+13% likely +4–6% move.Driver 2 · Capex & D&A step-up compresses multiples (Debates 2 & 3)
Claim: Four of the last five prints (excluding 4Q25’s +10.5pp rally) coincided with −5.8pp to −10.3pp excess drops as capex guidance rose. Our $234.9bn FY27E capex puts EPS −7.0% below Street ($31.58 vs $33.97) yet leaves +20.7% target upside. Watch: FY27 capex guide (est. late Jan 2027) — Penmark $234.9bn vs $250bn+ bear views.Driver 3 · Muse & Business AI shift from Q&A to revenue (Debate 3)
Claim: Analysts asked about Muse/Meta AI on 36 of 65 turns (55.4%) with confident management answers on 10x compute efficiency and >$200 Muse commerce orders, yet price assigns ~$0. We model +75% FoA Other to $7.40bn in FY27E ($23.19bn by FY30E). Watch: FY27 FoA Other run-rate ($1.5bn+ quarterly confirms +75% ramp).Driver 4 · Discount-rate & beta shifts govern our rating (Debates 1 & 3)
Claim: Because FCF is negative through FY28E (−$80.6bn FY27E, −$40.2bn FY28E; +$6.6bn FY29E), equity duration is long. Raising discount rate +1pt cuts our rolled target −$123.5/sh to $650.8 (+1.5%, Hold); high-beta cuts it to $598.9 (−6.6%, Hold). Watch: Credit spreads on $15bn Nov 2026 notes (5.85%–7.50%) & FY27 ATM execution.| Candidate tested | Common market assumption | Why empirical tests rejected it as a primary driver |
|---|---|---|
| China cross-border ad spend | Tariff/de-minimis shocks derail ad growth | Only 4.6% of Q&A turns (combined macro/China/EU); global auction re-allocated impressions to domestic & AI-assisted SMBs with 3Q26 ad price accelerating to +14%. |
| Reality Labs quarterly revenue | Headset unit swings move META shares | RL is 1.1% of FY25A sales ($2.2bn); stock reacts only to annual RL operating-loss cap (~−$15bn FY27 guide), folded into Driver 2/margin floor. |
| One-off legal accruals & tax | $9.89bn 3Q26 AG charge drives valuation | Market looked through $3.83 GAAP vs $7.40 ex-charge EPS on 3Q26 print (−5.8pp move tracked capex guide); model deducts $19.88bn balance-sheet liability directly. |
| DAP headline user additions | Mature user saturation caps revenue | DAP grew steadily +3% to 3.64bn with low variance; ARPP (+22% y/y in 3Q26) and price/ad explain >85% of top-line variance. |
Source: Penmark Research driver screening across company KPIs, 8 earnings transcripts and Nasdaq event windows.
Methodology & limits: Quarterly operating correlations (n = 20 quarters) and event windows (n = 5–8 prints) describe co-movement rather than causality; Q&A shares reflect Penmark’s internal coding of 65 analyst question turns across company earnings transcripts.
AI ranking drives +21.0% FY27E ad growth, from +11% price and +9% impressions, clearing the 12.5% implied bar by 8.5pp
Source: Penmark Research model (FY23A–FY27E FoA ad revenue y/y growth; FY27E scenario rates labelled at right).
2 · What the market believes
Sell-side revenue consensus ($312.6bn FY27E, +21.7%) looks aligned with our $313.1bn (+21.8%), yet the share price ($641.37; 21.8x published forward P/E, 20.3x on our FY27E EPS) discounts a sharp slowdown. Holding peer multiple and base margins fixed, $641.37 solves for just 12.52% FY27E ad growth—an immediate 15.3pp deceleration from FY26E’s +27.8%. Bears argue Reels ad load is full and 2026 pricing comps (+12% to +14%) will roll over in 2027.
3 · What it is worth per share
Clearing the 12.5% implied hurdle at our 21.0% base ad forecast generates +$75.47/sh (+11.8%) of present value ($716.84 vs $641.37). In our sensitivity matrix, each ±2pp shift in FY27E ad price growth moves primary P/E value by ±$19.43 per share ($697.4 to $736.3, ±2.7%), while our Bear pricing path (+6.5%, −4.5pp) cuts value −$47.2/sh. Bull ad growth of 24.9% lifts value toward $962.94.
| Evidence source | Observed quantitative proof (period & filing) | Why it supports +11.0% price & +9.0% impressions in FY27E |
|---|---|---|
| 1. Reported KPI series (Form 10-Q) | Ad price growth accelerated from +6% (4Q25) to +12% (1Q26), +12% (2Q26) and +14% (3Q26) while impressions grew +10% in 3Q26. | Proves price acceleration is auction-conversion driven, not supply scarcity: impressions still expanded double digits simultaneously. |
| 2. Model-level AI conversion lifts (3Q26 call) | GEM expansion lifted offsite campaign conversions +1.7% and app-ad conversions +9.6%; Andromeda added +1.4%; Feed generative retrieval added ~+2%. | In a second-price/VCG performance auction, higher conversion probability mechanically raises advertiser bids per impression without hurting ROAS. |
| 3. Advertiser tool adoption & agency benchmarks | Nearly 10m advertisers used GenAI creative tools in 3Q26; Business Assistant users raised ad spend +9%; Partnership Ads hit >$15bn run-rate (+97% y/y); IAB US social spend rose +32.6%. | Automated creative and creator partnerships broaden auction density across millions of SMBs, insulating pricing from single-vertical pullbacks. |
Source: Meta Q3 2026 Form 10-Q, Q3 2026 earnings transcript, and IAB/PwC Internet Advertising Revenue Report.
Consensus under-models FY27E D&A of $47.6bn, yet $31.58 EPS, 7.0% below Street, still backs $774.27
Source: Company filings; Penmark Research model (FY24A–FY32E D&A and GAAP operating margin; FY26E includes $9.89bn 3Q26 legal charge).
2 · What the market believes
Sell-side FY27E EPS drifted from $34.92 to $34.03 over 90 days and sits at $33.97 today (39 cuts vs 7 raises in 30 days), while equity investors fear a 2022-style margin collapse toward 20%. Published FY27E EBITDA estimates span ~$173bn–$183bn (vs our $182.3bn EBITDA+SBC), indicating our −7.0% EPS gap vs Street stems from D&A ($47.6bn), cloud/AI serving costs (36.5% FoA cash cost ratio), and 2,670m diluted shares (+2.8% vs consensus).
3 · Valuation impact (what it is worth)
Absorbing the −$2.39/sh consensus EPS haircut upfront removes negative revision risk while preserving $716.84 base value ($774.27 rolled 12m target). Each ±2pp move in FoA cash operating cost ratio (36.5% base) shifts P/E value by ∓$44.86/sh (±6.3%). Because EBITDA margin rebounds from 42.3% (FY26E) to 47.7% (FY27E) and 50.0% (FY28E), cash earnings absorb the D&A wave.
| Evidence source | Observed quantitative proof (period & filing) | Why it prevents a 2022-style margin collapse |
|---|---|---|
| 1. Non-capex headcount & AI efficiency (3Q26 release) | Headcount fell −15% y/y to 66,775 in 3Q26; first-party Muse models cut content-processing costs >80%, with management targeting >10x compute efficiency gains. | Caps the FoA cash cost peak at 36.5% in FY27E (+7.7pp vs FY25A on cloud/serving) before easing 50–100bps/yr from FY28E. |
| 2. Reality Labs explicit loss cap (3Q26 guidance) | Management guided FY26E Reality Labs operating loss to $18bn–$19bn and explicitly framed FY27E RL loss around −$15.0bn. | Narrows RL drag from 9.6% of sales in FY25A ($19.2bn) to 4.8% in FY27E ($15.0bn / $313.1bn) and 3.5% in FY28E ($13.0bn). |
| 3. Model PP&E D&A schedule (10-Q / Model) | Modelled at 12.0% of opening net PP&E plus 5.0% of in-year capex (blending 5.5-yr servers and 25-yr buildings), D&A rises to $47.6bn (FY27E) and $70.5bn (FY28E). | Spreads the FY26E–28E GPU cohort across multi-year revenue compounding rather than expensing it in a single fiscal year. |
Source: Company filings and Q3 2026 transcript; Penmark Research model.
Assumed 75% FY27E capex (−$80.6bn FCF) needs ~$195bn 4Q26–28E funding incl. $35bn FY28E notes
Source: Penmark Research model (company/model FCF = CFO less capex incl. finance leases, FY24A–FY32E).
2 · What the market believes
Bear estimates of $250bn+ after the 3Q26 print ($711.38/sh implied value) treat negative FCF as permanent value destruction, leaving our $234.9bn base +$5.47/sh less bearish. Simultaneously, the market assigns near-zero standalone value to Muse, Meta One and WhatsApp Business AI—even though they featured in 55.4% of analyst Q&A.
3 · Valuation gap & Low-conviction honesty
This capex hump explains the $214.58 gap between our primary P/E value ($716.84) and 2040 DCF cross-check ($502.26): DCF discounts −$221.8bn of negative unlevered FCF over 4Q26E–FY29E (−$133.2bn company FCF over 4Q26E–FY28E) upfront at 10.80% WACC, whereas P/E captures that build via the multi-year D&A step-up. Because +1pt discount rate ($650.78 target) or high beta ($598.85) flips our Buy to Hold, conviction is Low.
| Evidence source | Observed quantitative proof (period & filing) | How it anchors our model forecast & funding bridge |
|---|---|---|
| 1. Commitments footnote (Q3 2026 Form 10-Q) | $454.5bn of non-cancelable purchase/data-centre commitments ($121.4bn due in 2027) plus $18.48bn venture leases (and $41.49bn non-probable residual guarantees). | Supports our aggressive 75.0% FY27E capex assumption ($234.9bn), fading to 66% (FY28E), 55% (FY29E), 46% (FY30E) and 25% terminal. |
| 2. Oct–Nov 2026 capital raises (Form 8-K filings) | $82.45bn 3Q26 cash/securities + $14.37bn 6.50% mandatory convertible preferred (23m shs) + $15.0bn senior notes (5.85%–7.50%) + Class C framework. | Covers ~$195bn of 4Q26E–28E cash needs (−$133.2bn FCF, $47.0bn RSU taxes, $15.1bn divs) via $42.4bn cash draw, $29.4bn 4Q26 raises, $88.7bn fwd/ATM eq. & $34.9bn FY28E notes to issue. |
| 3. Muse & Meta One early KPIs (3Q26 call) | >10m US/Canada Muse setups in ~6 weeks (~25% DAU; >25% shopping at >$200 basket); Meta One >15m subs/trials; Meta AI engagement/user >2x since Apr. | Backs FoA Other revenue growing +64% to $4.23bn (FY26E), +75% to $7.40bn (FY27E) and $23.19bn by FY30E. |
Source: Meta Q3 2026 Form 10-Q, Form 8-K filings (Oct–Nov 2026), Q3 2026 transcript, and Penmark Research model.
Operating cash flow doubled to $115.8bn between FY21A and FY25A, while SBC ($20.4bn) & $454.5bn commitments require care
Meta’s GAAP earnings convert cleanly to operating cash flow (191.5% CFO/net income in FY25A), because advertising collects in ~35 days with zero inventory. Three accounting items dominate analysis: SBC, legal accruals and off-balance-sheet GPU commitments.
| Metric ($m unless noted) | FY21A | FY22A | FY23A | FY24A | FY25A | 3Q26A |
|---|---|---|---|---|---|---|
| Revenue | $117,929 | $116,609 | $134,902 | $164,501 | $200,966 | $64,601 |
| Revenue growth y/y (ad imps / ad price) | +37.2% | −1.1% | +15.7% | +21.9% | +22.2% | +26.1% (+10/+14%) |
| GAAP operating income (EBIT) | $46,753 | $28,944 | $46,751 | $69,380 | $83,276 | $12,988* |
| GAAP operating margin | 39.6% | 24.8% | 34.7% | 42.2% | 41.4% | 20.1% (35.4% ex-AG) |
| Stock-based compensation (SBC) | $9,164 | $11,992 | $14,027 | $16,690 | $20,427 | ~$7,200 |
| Operating cash flow (CFO) | $57,683 | $50,475 | $71,113 | $91,328 | $115,800 | $32,790 |
| Capex incl. finance-lease principal (model/co.) | — | — | $28,103 | $39,225 | $72,215 | $34,905 |
| Free cash flow (company/model definition) | — | — | $43,010 | $52,103 | $43,585 | −$2,120 |
| Memo: Purchases of property & equipment (GAAP) | $18,567 | $31,431 | $27,266 | $37,256 | $69,691 | $33,942 |
| Diluted EPS (GAAP, $) / CFO-to-NI conversion | $13.77 / 147% | $8.59 / 218% | $14.87 / 182% | $23.86 / 146% | $23.49 / 192% | $3.83 / 333% |
Source: Company filings; Penmark Research model (FY21A–FY25A & 3Q26A; lease-inclusive capex and company FCF reported from FY23A onward). *3Q26 includes $9.89bn AG legal accrual ($7.40 adj. EPS vs $3.83 GAAP).
Source: Company Form 10-K GAAP cash flow and income statements (FY21A–FY25A; FY25A net income reflects $25.47bn tax provision).
| Item | Reported size & Penmark treatment |
|---|---|
| SBC ($20.4bn FY25A; 10.2% rev) | Real economic cost: Never added back to GAAP EPS; deducted as a cash-equivalent cost in our 2040 DCF ($32.9bn FY27E). |
| PP&E D&A (12% open / 5% capex) | Model blends 5.5-yr server & 25-yr building lives via 12.0% opening PP&E + 5.0% in-year capex D&A, lifting D&A to $47.6bn (FY27E) and $90.7bn (FY29E). |
| Legal accruals ($19.88bn 3Q26) | 3Q26 booked $9.89bn AG charge (FY26E GAAP EPS $28.89 vs $33.42* ex-charge); we deduct full $19.88bn ($11.58bn curr. + $8.30bn non-curr.) from equity value. |
| Commitments ($454.5bn) | $121.4bn due 2027 + $18.48bn venture leases anchored in our capex/lease build; $41.49bn max residual guarantees excluded as not probable. |
Source: Meta Q3 2026 Form 10-Q; Penmark model. *FY26E includes a $5.0bn tax benefit booked in 1Q26; the FY26E tax rate is 6.5% vs 16% in FY27E.
Revenue scales from $201.0bn in FY25A to $313.1bn in FY27E and $477.6bn in FY30E on AI ad yield & FoA Other
Source: Meta Form 10-K and 3Q26 10-Q (FY24A–9M26A); Penmark Research model (FY27E–FY30E Family of Apps ad volume & pricing assumptions).
Source: Penmark Research model (FY24A–FY30E segment revenue in $bn).
Reasoning behind each revenue line
Family of Apps Advertising ($250.7bn FY26E → $303.3bn FY27E → $450.9bn FY30E): After +27.8% growth in FY26E, we model ad impressions decelerating smoothly from +9.0% (FY27E) to +8.0% (FY28E), +7.0% (FY29E) and +6.0% (FY30E) as Reels and Threads ad load matures. Average price per ad tapers from +11.0% (FY27E) to +8.0%, +6.5% and +5.5% as GEM/Andromeda conversion gains lap tough comps.
FoA Other ($4.23bn FY26E → $7.40bn FY27E → $23.19bn FY30E): Grows +75% in FY27E, +60% in FY28E, +45% in FY29E and +35% in FY30E on WhatsApp paid messaging, Meta One (>15m base) and Muse commerce take-rates. Reality Labs grows 12–15%/yr ($2.41bn → $3.57bn) on Ray-Ban/AI glasses.
| Line item | Penmark | Guide / Cons. | Gap | Primary analytical reason for difference |
|---|---|---|---|---|
| 4Q26E revenue ($m) | $75,373 | $75,155 cons | +0.3% | Near top of $73,000–$76,000m guide (incl. ~1% FX headwind) on +14% 3Q ad pricing momentum. |
| FY26E total expenses ($m) | $176,035 | $175,000–$179,000 guide | In-line | Includes $9.89bn 3Q26 AG legal accrual; FY26E GAAP EPS $28.89 vs $29.12 cons (−0.8%). |
| FY27E revenue ($m) | $313,139 | $312,630 cons | +0.2% | 59-analyst consensus ($312.6bn, 10 Nov 26) matches our +21.0% ad & +75% FoA Other build. |
| FY27E EBITDA + SBC ($m) | $182,311 | $183,283* | −0.5% | Published EBITDA listings span ~$173bn–$183bn; cash operating profitability matches Street. |
| FY27E diluted EPS ($) | $31.58 | $33.97 cons | −7.0% | Higher D&A ($47.6bn), FoA cloud/serving costs (36.5%), net interest (−$1.44bn) & 2,670m diluted shares (+2.8% vs Street). |
| FY27E capex / FCF ($m) | $234,854 / −$80,555 | $217,172 / −$46,956 | +8.1% capex | 75.0% capex/rev peak assumption vs ~30 Oct 26 FCF-implied Street capex ($170.2bn CFO − $217.2bn). |
Source: Penmark Research model; Yahoo Finance consensus (rev/EPS 10 Nov 2026; NI/OCF/FCF ~30 Oct 2026; *workbook consensus EBITDA+SBC benchmark).
EBITDA margin rebounds to 54.6% by FY30E while gross debt peaks at $158.6bn to defend a $40bn cash floor
Meta’s cost base splits cleanly between scalable FoA cash costs (36.5% → 34.0% of FoA revenue in FY27E–30E) and semi-fixed GPU depreciation ($18.6bn → $107.1bn). Hybrid financing bridges negative FY26E–28E FCF without breaching investment-grade leverage (peak 0.53x net debt/EBITDA).
| Metric ($bn unless noted) | FY24A | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|---|---|
| FoA cash operating cost % FoA rev | 26.5% | 28.8% | 34.3% | 36.5% | 36.0% | 35.0% | 34.0% |
| Reality Labs operating loss ($bn) | −$17.7 | −$19.2 | −$18.4 | −$15.0 | −$13.0 | −$11.0 | −$9.0 |
| EBITDA ($bn) / EBITDA margin | $84.9 / 51.6% | $101.9 / 50.7% | $108.8 / 42.3% | $149.4 / 47.7% | $184.2 / 50.0% | $222.0 / 52.4% | $260.9 / 54.6% |
| Depreciation & amortisation ($bn) | $15.5 | $18.6 | $27.8 | $47.6 | $70.5 | $90.7 | $107.1 |
| Operating income ($bn) / margin | $69.4 / 42.2% | $83.3 / 41.4% | $81.1 / 31.5% | $101.8 / 32.5% | $113.6 / 30.8% | $131.3 / 31.0% | $153.8 / 32.2% |
| Capex incl. leases ($bn) / % rev | $39.2 / 23.8% | $72.2 / 35.9% | $140.0 / 54.5% | $234.9 / 75.0% | $243.2 / 66.0% | $232.9 / 55.0% | $219.7 / 46.0% |
| Free cash flow ($bn) | $52.1 | $43.6 | −$1.4 | −$80.6 | −$40.2 | +$6.6 | +$56.5 |
| Cash & securities / Gross debt ($bn) | $77.8 / $28.8 | $81.6 / $58.7 | $93.5 / $98.7 | $44.8 / $98.7 | $40.0 / $133.5 | $40.0 / $158.6 | $63.4 / $158.6 |
| Diluted shares (m) / Net debt/EBITDA | 2,614 / −0.58x | 2,574 / −0.22x | 2,576 / 0.05x | 2,670 / 0.36x | 2,716 / 0.51x | 2,740 / 0.53x | 2,740 / 0.36x |
Source: Penmark Research model (FY26E EBITDA/EBIT reflect $9.89bn 3Q26 legal charge).
Source: Company filings; Penmark Research model ($14.37bn preferred + $15.0bn Nov 26 notes + $28.7bn fwd + $60bn FY27–28 ATM + $34.9bn FY28E & $25.0bn FY29E cash-floor notes).
Source: Penmark Research model (9 Nov 2026 primary P/E base value across ±2pp FY27E ad-price & FoA cash cost shifts; all cells exceed $641.37).
Working capital, capex & financing mechanics
Receivables scale with sales ($19.8bn FY25A → $27.5bn FY27E), while payables/accruals partially offset working-capital absorption. Including $14.37bn Oct preferred (23m shs), 46m forward-sale shares and $60bn FY27–28 ATM, diluted shares reach 2,739.7m by FY29E.
Operating sensitivity takeaway
Across every cell of our ±2pt operating matrix ($653.3 to $781.9), present value stays above $641.37 (and rolled 12m value exceeds $723). Operational misses alone barely dent Buy; multiple/discount-rate shifts carry the real downside.
Peer-median 22.94x FY27E P/E yields $716.84 base value and a $774.27 rolled target, +20.7% and a Buy
We value Meta primarily on peer-median forward P/E (22.94x FY27E EPS ex legal charges, less per-share legal accruals), cross-checked against an explicit FCFF DCF to FY2040 ($502.26). Peer P/Es are as published on 6 Nov and priced at the 9 Nov close (META 21.8x published forward; 20.3x on our FY27E EPS).
| Primary P/E & target build | Value |
|---|---|
| FY27E diluted EPS (ex legal charges) | $31.58 |
| Peer-median forward P/E (GOOGL, AMZN, MSFT, APP) | 22.94x |
| Gross operating equity value per share | $724.36 |
| Less: 3Q26 legal accruals ($19,881m / 2,646.2m shs) | −$7.51 |
| Base-case primary value (at 9 Nov 2026) | $716.84 |
| Bear ($448.05 × 25%) + Base ($716.84 × 55%) + Bull ($962.94 × 20%) | $698.86 |
| 1-yr roll-forward to 9 Nov 2027 (Ke net of div ~10.79%) | ×1.1079 |
| 12-month price target (probability-weighted) | $774.27 |
| Share price (9 Nov 2026) / Price return (Buy >+10%) | $641.37 / +20.7% |
| FY27E dividend yield / 12m total return | 0.34% / +21.1% |
Source: Penmark Research model (exact unrounded return +20.72%).
Source: Penmark Research model; Yahoo Finance Street targets.
| 2040 FCFF DCF component | Base value |
|---|---|
| WACC / Terminal growth / Terminal RONIC | 10.80% / 3.0% / 15.0% |
| PV of explicit FCFF (4Q26E–FY40E; SBC = cash cost) | $498,560m |
| PV of terminal value (at FY40E) | $752,070m |
| DCF enterprise value | $1,250,630m |
| Plus cash, investments & hybrid / less debt & legal | +$63,165m adj. |
| DCF equity value / share (2,646.2m shs, 30 Sep 2026) | $496.48 |
| DCF base value rolled to 9 Nov 2026 | $502.26 |
| Gap vs primary P/E base ($716.84 − $502.26) | −$214.58 (−29.9%) |
Source: Penmark Research model.
Source: Penmark Research model (column width = probability weight).
At $641.37 the market prices 20.55x FY27E P/E or 12.5% ad growth; +1pt rate cuts value −$121/sh
Source: Penmark Research model (DCF value rolled to 9 Nov 2026).
| Variable solved for $641.37 | Price-implied | Penmark Base |
|---|---|---|
| FY27E P/E (incl. $7.51 legal adj.) | 20.55x | 22.94x peer med |
| FY27E P/E (simple price / EPS) | 20.31x | 24.52x at target |
| FY27E ad revenue growth | 12.52% | 21.00% (+8.5pp) |
| DCF WACC (at 3.0% term. g) | 9.58% | 10.80% (+122bps) |
| DCF terminal growth (at 10.8% WACC) | 7.28% | 3.00% |
| EV / FY27E EBITDA (actual / target) | 10.93x | 13.28x at target |
Source: Penmark Research model.
| Scenario (subjective weight) | FY27E ad imps / price | FoA cash cost | FY27E capex | Target P/E | 9 Nov value | 12m target | Price ret. / Call |
|---|---|---|---|---|---|---|---|
| Bear case (25.0% weight) | +7.0% / +6.5% (+14.0%) | 38.5% | $258.7bn (88%) | 18.10x (GOOGL) | $448.05 | $496.39 | −22.6% (Sell) |
| Base case (55.0% weight) | +9.0% / +11.0% (+21.0%) | 36.5% | $234.9bn (75%) | 22.94x (median) | $716.84 | $794.19 | +23.8% (Buy) |
| Bull case (20.0% weight) | +11.0% / +12.5% (+24.9%) | 35.0% | $220.9bn (68%) | 27.20x (MSFT) | $962.94 | $1,066.85 | +66.3% (Buy) |
| Probability-weighted outcome | — | — | — | 23.0x FY28E (24.5x FY27E) | $698.86 | $774.27 | +20.7% (Buy) |
Source: Penmark Research model (2040 DCF cross-check values: Bear $246.36, Base $502.26, Bull $720.65, Weighted $481.96). Limits note: scenario weights (25% / 55% / 20%) are subjective analyst judgements reflecting right-skewed AI ad upside vs capex/multiple downside.
Source: Penmark Research model (one-at-a-time driver shocks around $716.84 base value at 9 Nov 2026).
January 2027 Class C dividend & estimated late-Jan 4Q26/FY27 capex guide anchor the 12-month catalyst path
Because four of the last five earnings prints coincided with capex-related sell-offs (4Q25 rallied +10.5pp), clearing initial FY27E capex guidance (est. late January 2027) is the top catalyst for our $774.27 target (+20.7%).
| Expected window | Catalyst event | Penmark expectation vs Street / guidance | Potential share-price / rating impact |
|---|---|---|---|
| ~19 Jan 2027 (expected) | Class C 1-for-1 non-voting stock dividend effective | 1 Class C share issued per Class A/B share; halves nominal share price mechanically while creating currency for $60bn FY27–28 ATM. | Neutral on intrinsic value; removes founder-control uncertainty around equity funding. |
| Late Jan 2027 (unconfirmed est.) | 4Q26 results & initial FY27 capex / expense guidance | 4Q26E rev $75.37bn vs $75.16bn cons ($73bn–$76bn guide); FY27 capex framed near $220bn–$240bn vs bear estimates of $250bn+ after 3Q26. | High (±6–10%): Capex ≤$235bn + 1Q27 ad growth >21% resets EPS floor; capex >$255bn threatens Buy. |
| Late Apr 2027 (est.) | 1Q27 results & 1H27 AI ad-pricing durability check | Ad price y/y holds ~+10% to +12% against +12% 1Q26 comp; FoA Other accelerates toward $1.5bn+ quarterly run-rate. | Medium-High (±5–8%): Confirms GEM/Andromeda conversion gains persist into year two. |
| 2Q27–3Q27 (May–Sep 2027) | Llama / Muse commerce & Meta Connect 2027 showcase | Expanded US/international Muse checkout (>$200 avg order), Meta One paid tier conversions (>15m base) & next-gen AI glasses. | Medium (+3–6%): Shifts 55.4% Q&A focus into tangible FY28E Street revenue upgrades. |
| Late Oct 2027 (est.) | 3Q27 results & first FY28E capex-to-sales peaking signal | Management signals FY28E capex moderating as % of sales (Penmark 66.0% vs 75.0% FY27E) and RL loss holding ≤$15bn. | High (+8–12%): Catalyst for multiple expansion from 20.3x on our FY27E EPS toward 23.0x target P/E on FY28E EPS. |
Source: Meta Form 8-K (21 Oct 2026) for expected 19 Jan 2027 Class C distribution; earnings dates are Penmark estimates based on historical reporting cadence (not yet formally scheduled by Meta).
| Section 9 driver (Debate) | Next metric & reporting date | Penmark vs Street | Threshold that changes our Buy rating (Hold band: −10.0% to +10.0%) |
|---|---|---|---|
| Driver 1: AI ad pricing (D1) | 4Q26 ad price y/y (est. late Jan 27) | ~+12.0% vs ~+11% | Sustained FY27E ad price <+6.5% cuts rolled target toward $705.51 (+10.0% Buy/Hold boundary at $641.37). |
| Driver 2: Capex & D&A (D2, D3) | FY27 capex guide (est. late Jan 27) | $234.9bn vs $250bn+ bear | FY27E capex >$255bn without revenue upside + 2.0x peer multiple compression moves target below $705.51 (Hold). |
| Driver 3: Muse / FoA Other (D3) | 4Q26 / 1Q27 FoA Other ($m) | $7.40bn FY27E (+75%) | Upside option: faster Muse GMV ramp lifts Bull weight above 20%, widening buffer above +10% Buy threshold. |
| Driver 4: Cost of equity (D1, D3) | 10Y UST / beta regime (ongoing) | 10.80% base WACC | Immediate trigger: +1pt discount rate cuts target to $650.78 (+1.5%, Hold); 1.57 beta cuts target to $598.85 (−6.6%, Hold). |
Source: Penmark Research model.
Two robustness tests flip Buy to Hold, anchoring Low conviction: a 1pt rate rise gives $651 and high beta $599
As a Buy-rated initiation, our risk analysis centres on downside threats to our $774.27 target and +20.7% expected return. Heavy near-term cash demands (~$195bn over 4Q26E–FY28E, incl. −$133.2bn FCF and ~$35bn of FY28E notes to issue) magnify sensitivity to discount rates, capex discipline and regulatory rulings.
Source: Penmark Market Check robustness tests ($650.78 target at +1pt rate = +1.5% Hold; $598.85 at 1.57 beta = −6.6% Hold).
What would end the Buy thesis outright
A simultaneous AI capex overrun (>$255bn FY27E) and ad-pricing stall (<+6.5% y/y) triggers our $448.05 Bear value ($496.39 rolled 12m target, −22.6% Sell). In that scenario, P/E on our FY27E EPS compresses from 20.3x to Alphabet’s 18.1x floor while FY27E EPS drops toward ~$25.2 on unrecovered D&A and financing dilution.
What moves Buy to Hold first: Even on base operations, +100bp WACC ($650.78 target, +1.5%) or 1.57 beta ($598.85, −6.6%) pulls expected return inside −10% to +10%.
| Risk category | Likelihood | Value / share impact | Mechanism, filing evidence & mitigation |
|---|---|---|---|
| 1. AI capex & commitment escalation | Medium-High | −$120 to −$269/sh (Bear $448.05) | $454.5bn non-cancelable commitments ($121.4bn in 2027) + $18.48bn venture leases + $41.49bn max residual value guarantees could lock in >70% capex/sales past FY28E if GPU obsolescence accelerates. |
| 2. Rate / beta multiple compression | Medium | −$123.5 to −$175.4/sh on 12m target | +1pt WACC cuts rolled target to $650.78 (+1.5% Hold); upper-end published beta (1.57) cuts target to $598.85 (−6.6% Hold). Wider credit spreads on ~$60bn of FY28E–29E cash-floor notes ($34.9bn FY28E, $25.0bn FY29E) raise interest drag, while lower equity prices increase share dilution on the $60bn FY27E–28E Class C ATM. |
| 3. Ad pricing & macro / AI substitution | Medium | −$19.4/sh per −2pp (−$47.2 Bear) | SMB ad budgets are macro-cyclical; retail media (Amazon $82.1bn) and external AI answer engines could siphon high-intent commercial queries. |
| 4. Legal, EU DMA & youth-safety rulings | Medium | −$7.51/sh accrued + EU margin risk | 3Q26 booked a $9.89bn AG charge (up to ~$18.59bn cash outflows; $19.88bn total balance-sheet legal accruals). EU “consent-or-pay” remedies threaten European ARPP ($14.23bn 3Q26 sales). |
| 5. Founder control, key-person & power ESG | Structural | Governance discount (~1–2x P/E) | Zuckerberg’s 60.8% vote + Class C structure remove external checks on capital allocation; grid-power & water permitting bottlenecks for multi-GW AI clusters represent a material operational ESG risk. |
| Upside risk against Low conviction | 20% Bull | +$292.6/sh to $1,066.85 target | Faster 10x inference efficiency cuts FY27E capex toward 68% of sales ($220.9bn) while Muse/Meta One scale, re-rating META to MSFT’s 27.2x multiple. |
Source: Meta Q3 2026 Form 10-Q, 2026 DEF 14A, and Penmark Research model.
Institutions held 76.8% of Class A at 2Q26, short interest is 1.3% at 1.8 days, and 88% of Street rates META Buy
Source: FINRA bi-weekly short interest through 15 Oct 2026 settlement (−15.4% vs 30 Sep; 1.80 days to cover).
Source: Yahoo Finance Street ratings (50 Buy incl. 3 Strong Buy, 7 Hold, 0 Sell; 10 Nov 2026).
Liquidity, index membership & supply overhangs
META trades $14.02bn/day (21.29m 3m avg daily shares) across S&P 500, Nasdaq-100 and XLC (~22% weight). Near-term equity supply comes from 23m mandatory preferred shares, 46m forward-sale shares, and our modelled $60bn FY27E–28E Class C ATM (~4.3 days of ADV).
Street positioning & crowding check
With 50 of 57 analysts rating META Buy (including 3 Strong Buy, 7 Hold, 0 Sell; $833.12 mean target and $650 Street low above $641.37), sell-side positioning is crowded bullish—reinforcing why our $31.58 EPS (−7.0% vs Street) and $774.27 target stay conservative.
| Institution (Q2 2026 13F) | Shares (m) | % Class A* |
|---|---|---|
| Vanguard Group | 204.86 | 9.29% |
| BlackRock | 173.40 | 7.86% |
| FMR LLC (Fidelity) | 95.90 | 4.35% |
| State Street | 92.03 | 4.17% |
| Geode Capital Management | 54.95 | 2.49% |
| JPMorgan Chase | 45.94 | 2.08% |
| Capital World Investors | 40.88 | 1.85% |
| Capital Research Global | 39.62 | 1.80% |
| Morgan Stanley | 39.44 | 1.79% |
| Invesco | 38.37 | 1.74% |
| Top 10 / Total 13F reported | 825.39 / 1,693.63 | 37.4% / 76.8% |
Source: SEC Form 13F filings for quarter ended 30 June 2026 (not Q3/Q4 2026; *% of 2,205.13m Class A shares outstanding basis).
Insider activity & Form 4 interpretation
Recent Form 4 filings reflect routine liquidity, derivative settlements and pre-arranged Rule 10b5-1 plans rather than directional insider views. Filings show a 4 Nov 2026 Zuckerberg derivative-leg disposition (97,935 shs at $633.80), 2 Nov Marc Andreessen sales ($606.85–$613.88), and Javier Olivan sales executed under a pre-arranged Rule 10b5-1 trading plan. Because Form 4 footnotes do not report plan indicators uniformly across every filer, we draw zero directional signal from aggregate insider sales.
Summary statements, balance sheet and valuation ratios: EPS reaches $44.54 by FY30E
| Income statement ($m) | FY23A | FY24A | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|---|---|---|
| Advertising revenue | $131,948 | $160,633 | $196,175 | $250,701 | $303,323 | $353,796 | $403,168 | $450,862 |
| FoA other + Reality Labs rev | $2,954 | $3,868 | $4,791 | $6,385 | $9,817 | $14,621 | $20,367 | $26,762 |
| Total revenue | $134,902 | $164,501 | $200,966 | $257,086 | $313,139 | $368,416 | $423,535 | $477,624 |
| Revenue growth y/y | +15.7% | +21.9% | +22.2% | +27.9% | +21.8% | +17.7% | +15.0% | +12.8% |
| EBITDA | $57,929 | $84,878 | $101,892 | $108,834 | $149,431 | $184,169 | $221,988 | $260,887 |
| EBITDA margin | 42.9% | 51.6% | 50.7% | 42.3% | 47.7% | 50.0% | 52.4% | 54.6% |
| Depreciation & amortisation | $11,178 | $15,498 | $18,616 | $27,783 | $47,638 | $70,519 | $90,725 | $107,129 |
| Operating income (EBIT) | $46,751 | $69,380 | $83,276 | $81,051 | $101,793 | $113,650 | $131,263 | $153,758 |
| Operating margin | 34.7% | 42.2% | 41.4% | 31.5% | 32.5% | 30.8% | 31.0% | 32.2% |
| Net interest/other & tax | −$7,653 | −$7,020 | −$22,818 | −$6,610 | −$17,498 | −$22,133 | −$26,806 | −$31,720 |
| GAAP net income | $39,098 | $62,360 | $60,458 | $74,440 | $84,295 | $91,517 | $104,457 | $122,037 |
| Diluted EPS (GAAP / ex-legal $)* | $14.87 | $23.86 | $23.49 | $28.89 / $33.42 | $31.58 | $33.69 | $38.13 | $44.54 |
| Cash flow & balance sheet ($m) | FY23A | FY24A | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|---|---|---|
| Stock-based compensation (SBC) | $14,027 | $16,690 | $20,427 | $28,440 | $32,880 | $36,842 | $40,236 | $42,986 |
| Operating cash flow (CFO) | $71,113 | $91,328 | $115,800 | $138,579 | $154,300 | $203,003 | $239,529 | $276,170 |
| Capex incl. finance leases | $28,103 | $39,225 | $72,215 | $140,000 | $234,854 | $243,155 | $232,944 | $219,707 |
| Free cash flow (model/co. def.) | $43,010 | $52,103 | $43,585 | −$1,421 | −$80,555 | −$40,151 | $6,585 | $56,463 |
| Dividends paid / Buybacks | $0 / $19,774 | $5,072 / $30,125 | $5,324 / $26,248 | $5,440 / $0 | $5,766 / $0 | $6,112 / $0 | $6,479 / $0 | $6,868 / $0 |
| Cash & marketable securities | $65,403 | $77,815 | $81,592 | $93,457 | $44,799 | $40,000 | $40,000 | $63,373 |
| Property & equipment, net | $96,587 | $121,346 | $176,400 | $299,129 | $486,345 | $658,981 | $801,200 | $913,778 |
| Gross debt ($m) | $18,385 | $28,826 | $58,744 | $98,669 | $98,669 | $133,541 | $158,564 | $158,564 |
| Net debt (net cash) ($m) | −$47,018 | −$48,989 | −$22,848 | $5,212 | $53,870 | $93,541 | $118,564 | $95,190 |
| Total stockholders’ equity | $153,168 | $182,637 | $217,243 | $310,215 | $459,287 | $588,125 | $701,211 | $833,145 |
| Ratios & valuation | FY23A | FY24A | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|---|---|---|
| Diluted shares (m) / Div./dil. sh | 2,629 / $0.00 | 2,614 / $1.94 | 2,574 / $2.07 | 2,576 / $2.11 | 2,670 / $2.16 | 2,716 / $2.25 | 2,740 / $2.36 | 2,740 / $2.51 |
| Book value / share ($) | $58.26 | $69.87 | $84.40 | $120.42 | $172.04 | $216.51 | $255.94 | $304.10 |
| ROE (GAAP) / ROCE | 28.0% / 30.4% | 37.1% / 36.2% | 30.2% / 34.2% | 28.2% / 23.7% | 21.9% / 21.1% | 17.5% / 17.8% | 16.2% / 16.6% | 15.9% / 16.6% |
| ROA / Net debt to EBITDA | 18.8% / −0.81x | 24.7% / −0.58x | 18.8% / −0.22x | 16.4% / 0.05x | 13.8% / 0.36x | 12.0% / 0.51x | 11.3% / 0.53x | 11.4% / 0.36x |
| P/E (ex-legal) at $641.37* | 43.1x | 26.9x | 27.3x | 19.2x (22.2x GAAP) | 20.3x | 19.0x | 16.8x | 14.4x |
| EV / EBITDA / P/B at $641.37 | 28.2x / 11.0x | 19.3x / 9.2x | 16.0x / 7.6x | 15.0x / 5.3x | 10.9x / 3.7x | 8.9x / 3.0x | 7.4x / 2.5x | 6.3x / 2.1x |
| FCF yield / Dividend yield | 2.6% / 0.0% | 3.1% / 0.30% | 2.6% / 0.32% | −0.1% / 0.33% | −4.7% / 0.34% | −2.3% / 0.35% | +0.4% / 0.37% | +3.2% / 0.39% |
| P/E at $774.27 target price | 52.1x | 32.5x | 33.0x | 23.2x | 24.5x | 23.0x | 20.3x | 17.4x |
Source: Company filings; Penmark Research model (cut-off 9 Nov 2026; buybacks $0 in 9M26A & FY26E–30E). *FY26E includes a $5.0bn tax benefit booked in 1Q26; the FY26E tax rate is 6.5% vs 16% in FY27E.
Quarterly/segment progression, GAAP-to-adjusted reconciliation, methodology and data cut-offs
| Segment, KPI & reconciliation | 1Q25A | 2Q25A | 3Q25A | 4Q25A | 9M26A | 4Q26E | FY26E | FY27E |
|---|---|---|---|---|---|---|---|---|
| Advertising revenue ($m) | $41,392 | $46,563 | $50,082 | $58,137 | $177,448 | $73,253 | $250,701 | $303,323 |
| FoA Other / Reality Labs rev ($m) | $510 / $412 | $583 / $370 | $690 / $470 | $801 / $955 | $2,989 / $1,276 | $1,242 / $879 | $4,231 / $2,155 | $7,403 / $2,413 |
| Total revenue ($m) | $42,314 | $47,516 | $51,242 | $59,893 | $181,713 | $75,373 | $257,086 | $313,139 |
| DAP (bn) / Ad imps / Ad price y/y | 3.43 / +5/+10% | 3.48 / +11/+9% | 3.54 / +14/+10% | 3.58 / +18/+6% | 3.64 / +14/+13% | 3.67 / +26% ad | 3.67 / +27.8% ad | 3.74 / +9/+11% |
| GAAP operating income ($m) | $17,555 | $20,441 | $20,535 | $24,745 | $54,635 | $26,416 | $81,051 | $101,793 |
| Plus: Legal settlement charges ($m) | $0 | $0 | $0 | $0 | $11,890* | $0 | $11,890* | $0 |
| Operating income ex-legal ($m) | $17,555 | $20,441 | $20,535 | $24,745 | $66,525 | $26,416 | $92,941 | $101,793 |
| GAAP EPS / EPS ex-legal ($) | $6.43 / $6.43 | $7.14 / $7.14 | $1.05 / $1.05 | ~$8.87 / $8.87 | $20.44 / $24.98 | $8.45 / $8.45 | $28.89 / $33.42† | $31.58 / $31.58 |
Source: Company filings; Penmark Research model (*9M26A legal charges = $9.89bn 3Q26 + $2.00bn 2Q26; 3Q25A EPS reflects $18,954m total tax provision, 87.5% effective rate). †FY26E includes a $5.0bn tax benefit booked in 1Q26; the FY26E tax rate is 6.5% vs 16% in FY27E.
| Topic / term | Penmark convention & known limits |
|---|---|
| Archetype | Advertising platform: users × engagement × price; revenue built as ad impressions growth × price-per-ad growth, plus FoA Other & RL hardware. |
| Primary vs rejected | Primary: Peer-median P/E (22.94x) on FY27E EPS ex-legal, less $7.52/sh legal accruals. Cross-check: FCFF DCF to 2040. Rejected: EV/EBITDA (ignores D&A step-up & venture leases), SOTP (RL is shared AI cost), FCF yield (negative through FY28E). |
| Share & SBC basis | Pre-Class C split basis (2,556.2m basic + 21m RSU + 46m fwd + 23m pref + ATM). SBC expensed in GAAP EPS & treated as cash cost in DCF. |
| Departures & limits | Annual + 9M26A/4Q26E stub replaces 4-quarter forecast grid (company guides FY expenses/capex & 1Q ahead revenue). Published 1.25 beta used (1.23–1.57 range tested). |
| Glossary | DAP: Family daily active people. ARPP: Quarterly rev / DAP. GEM / Andromeda: GPU ad ranking & retrieval models. Muse: Meta consumer/commerce AI assistant. |
| Reference | Definition & as-of date |
|---|---|
| Valuation peers (9 Nov 26) | Alphabet (GOOGL, 18.10x), Amazon (AMZN, 25.05x), Microsoft (MSFT, 27.20x), AppLovin (APP, 20.83x); median 22.94x (fwd EPS published 6 Nov, priced 9 Nov). |
| Peer P/E basis | Peer forward P/Es are as published on 6 Nov and priced at the 9 Nov close (META 21.8x on published forward basis vs 22.94x peer median; 20.3x on our $31.58 FY27E EPS). |
| Key ratio formulas | Model FCF: CFO − capex incl. finance-lease principal. ROCE: EBIT / average (equity + gross debt). Model EV: $1,634.0bn (2,646.2m dil. shs × $641.37 − $63.2bn net cash/bridge; 3Q26 basic EV $1,640.7bn). |
| Model cut-off | Model run 11 Nov 2026 on 9 Nov 2026 closing price ($641.37); USD reporting currency; FYE 31 Dec. |
| External data dates | SEC filings/KPIs: through 3Q26 10-Q (22 Oct 26) & 5 Nov 26 8-K. Consensus: Yahoo Finance rev/EPS 10 Nov 26; NI/FCF ~30 Oct 26. 13F: QE 30 Jun 26. Short int.: 15 Oct 26. |
Analyst certification and important disclosures
Ratings
Ratings are based on the upside from the share price to our 12-month price target, excluding dividends. The price target is weighted across bull, base and bear scenarios.
| Buy | Upside to price target above +10% |
| Hold | Upside to price target from −10% to +10%, inclusive |
| Sell | Upside to price target below −10% |
We review ratings at each set of results and whenever the facts change materially. A share price can move outside its band before the rating changes, and targets may not be reached.
Analyst certification
The Penmark Team certifies that (1) the views in this report accurately reflect its views about the subject company and its securities, and (2) no part of its compensation was, is or will be directly or indirectly related to the specific ratings, price targets or views in this report.
Contact
Penmark Research
Questions about our research:
research@penmarkresearch.com
All our research and coverage:
penmarkresearch.com
Basis of preparation
This report uses information publicly available up to its publication date. Share prices are closing prices on the trading day before the publication date, unless stated otherwise. Forecasts, valuations and price targets are Penmark Research’s own, and forecast periods are marked E. Sources are shown beneath each exhibit.
Valuation and price targets
Price targets are based on the valuation methods set out in each report and are weighted across bull, base and bear scenarios. The main risks to each rating and price target are described in the report. Penmark Research updates its coverage after each set of results but is not obliged to update a report at any other time.
Independence and conflicts of interest
Penmark Research is independent. It does not provide investment banking, brokerage, market-making or asset management services, does not trade securities, and does not accept payment from any company for research coverage. Companies do not see or review Penmark Research reports before publication.
No member of the Penmark Team holds a long or short position, directly or through derivatives, in the securities of any company Penmark Research covers.
Regulatory status
Penmark Research publishes general, impersonal investment research on a regular basis. It is not registered as an investment adviser with the US Securities and Exchange Commission or any state securities authority, is not a registered broker-dealer and is not a member of FINRA. Penmark Research does not give advice tailored to any person’s circumstances.
Not investment advice or an offer
This report is for information only. It is not personalised investment advice and is not an offer or solicitation to buy or sell any security or other financial instrument. It does not take into account any reader’s objectives, financial situation or needs. Readers should make their own investment decisions and seek independent professional advice where appropriate.
Forward-looking statements and risk
Forecasts, valuations and price targets are estimates based on assumptions that may prove wrong, and they may not be achieved. Opinions are current as of the publication date and may change without notice. Investing in equities involves risk, including the loss of capital. Share prices can be volatile, and past performance is not a reliable indicator of future results.
Data and sources
Company financials, operating data and filings come from company filings, earnings releases and earnings calls. Market data and any consensus estimates come from third-party sources named beneath the relevant exhibit; consensus figures from aggregators are unofficial. Penmark Research does not use other brokers’ research. Third-party data belong to their providers and may not be extracted from this report.
Accuracy and liability
Information is taken from sources believed to be reliable, but Penmark Research makes no representation or warranty as to its accuracy, completeness or timeliness. To the fullest extent permitted by law, Penmark Research accepts no liability for any loss arising from use of this report. Descriptions of litigation and regulatory matters reflect allegations and public records, not findings, unless stated. If a published report is corrected, the corrected version carries an “Updated” date at penmarkresearch.com.
Distribution and access
Penmark Research reports are available to registered users of penmarkresearch.com. Downloads and programmatic access are governed by the Penmark Research subscription terms. This report is not directed at, or intended for, any person in Singapore or India, and access from those countries is blocked. It is not intended for distribution to, or use by, any person in any jurisdiction where that would be contrary to law or regulation or would subject Penmark Research to registration or licensing requirements there.
Copyright and permitted use
© Penmark Research. All rights reserved. Penmark Research is a trade name of Brightriver Labs. Readers may share a link to this report but may not copy, reproduce, redistribute, sell or use its content, including for text and data mining, without written consent. Contact: research@penmarkresearch.com.